Cargando…
晚期非小细胞肺癌靶向治疗进展与展望:聚焦小分子酪氨酸激酶抑制剂
At present the treatment of advanced non-small cell lung cancer enters a targeted era and develops rapidly. New drugs appear constantly. Small molecular tyrosine kinase inhibitors have occupied the biggest piece of the territory, which commonly have a clear biomarker as predictor, and show remarkabl...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999678/ https://www.ncbi.nlm.nih.gov/pubmed/28442018 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.04.09 |
_version_ | 1783331476199178240 |
---|---|
collection | PubMed |
description | At present the treatment of advanced non-small cell lung cancer enters a targeted era and develops rapidly. New drugs appear constantly. Small molecular tyrosine kinase inhibitors have occupied the biggest piece of the territory, which commonly have a clear biomarker as predictor, and show remarkable effect in specific molecular classification of patients. The epidermal growth factor tyrosine kinase inhibitors such as gefitinib, erlotinib, icotinib and anaplastic lymphoma kinase tyrosine kinase inhibitors crizotinib have brought a milestone advance. In recent years new generations of tyrosine kinase inhibitors have achieved a great success in patients with acquired resistance to the above two kinds of drugs. At the same time new therapeutic targets are constantly emerging. So in this paper, we reviewed and summarized the important drugs and clinical trails on this topic, and made a prospect of the future development. |
format | Online Article Text |
id | pubmed-5999678 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-59996782018-07-06 晚期非小细胞肺癌靶向治疗进展与展望:聚焦小分子酪氨酸激酶抑制剂 Zhongguo Fei Ai Za Zhi 综述 At present the treatment of advanced non-small cell lung cancer enters a targeted era and develops rapidly. New drugs appear constantly. Small molecular tyrosine kinase inhibitors have occupied the biggest piece of the territory, which commonly have a clear biomarker as predictor, and show remarkable effect in specific molecular classification of patients. The epidermal growth factor tyrosine kinase inhibitors such as gefitinib, erlotinib, icotinib and anaplastic lymphoma kinase tyrosine kinase inhibitors crizotinib have brought a milestone advance. In recent years new generations of tyrosine kinase inhibitors have achieved a great success in patients with acquired resistance to the above two kinds of drugs. At the same time new therapeutic targets are constantly emerging. So in this paper, we reviewed and summarized the important drugs and clinical trails on this topic, and made a prospect of the future development. 中国肺癌杂志编辑部 2017-04-20 /pmc/articles/PMC5999678/ /pubmed/28442018 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.04.09 Text en 版权所有©《中国肺癌杂志》编辑部2017 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | 综述 晚期非小细胞肺癌靶向治疗进展与展望:聚焦小分子酪氨酸激酶抑制剂 |
title | 晚期非小细胞肺癌靶向治疗进展与展望:聚焦小分子酪氨酸激酶抑制剂 |
title_full | 晚期非小细胞肺癌靶向治疗进展与展望:聚焦小分子酪氨酸激酶抑制剂 |
title_fullStr | 晚期非小细胞肺癌靶向治疗进展与展望:聚焦小分子酪氨酸激酶抑制剂 |
title_full_unstemmed | 晚期非小细胞肺癌靶向治疗进展与展望:聚焦小分子酪氨酸激酶抑制剂 |
title_short | 晚期非小细胞肺癌靶向治疗进展与展望:聚焦小分子酪氨酸激酶抑制剂 |
title_sort | 晚期非小细胞肺癌靶向治疗进展与展望:聚焦小分子酪氨酸激酶抑制剂 |
topic | 综述 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999678/ https://www.ncbi.nlm.nih.gov/pubmed/28442018 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.04.09 |
work_keys_str_mv | AT wǎnqīfēixiǎoxìbāofèiáibǎxiàngzhìliáojìnzhǎnyǔzhǎnwàngjùjiāoxiǎofēnzilàoānsuānjīméiyìzhìjì |